08:40 AM EDT, 10/19/2026 (MT Newswires) -- Merck KGaA (MRK.F) agreed to acquire London-based short interfering RNA therapies developer Silence Therapeutics in a deal with an enterprise value of $1.1 billion and an equity value of $1.3 billion. The German science and technology company will pay $20 in cash per American depositary share, each representing three ordinary shares of Silence Therapeutics, or $6.6667 per ordinary share, according to a Monday release. It will fund the deal through proceeds from new debt. Deal closing is set for the first quarter of 2027, subject to satisfaction of customary closing conditions.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.